Cas:586965-53-9 5-bromo-1H-imidazole-4-carbonitrile manufacturer & supplier

We serve Chemical Name:5-bromo-1H-imidazole-4-carbonitrile CAS:586965-53-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-bromo-1H-imidazole-4-carbonitrile

Chemical Name:5-bromo-1H-imidazole-4-carbonitrile
CAS.NO:586965-53-9
Synonyms:qc-8039
Molecular Formula:C4H2BrN3
Molecular Weight:171.98300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.47000
Exact Mass:170.94300
LogP:1.04388

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like qc-8039 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,qc-8039 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,qc-8039 Use and application,qc-8039 technical grade,usp/ep/jp grade.


Related News: Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 5-bromo-1H-imidazole-4-carbonitrile manufacturer Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 5-bromo-1H-imidazole-4-carbonitrile supplier What’s the background? 5-bromo-1H-imidazole-4-carbonitrile vendor Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 5-bromo-1H-imidazole-4-carbonitrile factory With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near